Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/242477
Type: Artigo de periódico
Title: Safe Use Of Biological Therapies For The Treatment Of Rheumatoid Arthritis And Spondyloarthritides
Author: Henrique da Mota
Licia Maria; Cruz
Boris Afonso; Brenol
Claiton Viegas; Pollak
Daniel Feldman; Castelar Pinheiro
Geraldo da Rocha; Magalhaes Laurindo
Ieda Maria; Pereira
Ivanio Alves; de Carvalho
Jozelio Freire; Bertolo
Manoel Barros; Pinheiro
Marcelo de Medeiros; Carioca Freitas
Max Victor; da Silva
Nilzio Antonio; Louzada-Junior
Paulo; Sampaio-Barros
Percival Degrava; Neubarth Giorgi
Rina Dalva; Correa Lima
Rodrigo Aires; Coelho Andrade
Luis Eduardo
Abstract: The treatment of autoimmune rheumatic diseases has gradually improved over the last half century, which has been expanded with the contribution of biological therapies or immunobiopharmaceuticals. However, we must be alert to the possibilities of undesirable effects from the use of this class of medications. The Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia) produced a document based on a comprehensive literature review on the safety aspects of this class of drugs, specifically with regard to the treatment of rheumatoid arthritis and spondyloarthritides. The themes selected by the participating experts, on which considerations have been established as the safe use of biological drugs, were: occurrence of infections (bacterial, viral, tuberculosis), infusion reactions, hematological, neurological, gastrointestinal and cardiovascular reactions, neoplastic events (solid tumors and hematologic neoplasms), immunogenicity, other occurrences and vaccine response. For didactic reasons, we opted by elaborating a summary of safety assessment in accordance with the previous themes, by drug class/mechanism of action (tumor necrosis factor antagonists, T-cell co-stimulation blockers, B-cell depletors and interleukin-6 receptor blockers). Separately, general considerations on safety in the use of biologicals in pregnancy and lactation were proposed. This review seeks to provide a broad and balanced update of that clinical and experimental experience pooled over the last two decades of use of immunobiological drugs for RA and spondyloarthritides treatment. (C) 2014 Elsevier Editora Ltda. All rights reserved.
Subject: Tumor-necrosis-factor
Anti-tnf Therapy
Congestive-heart-failure
Factor-alpha Therapy
Chronic Hepatitis-b
Modifying Antirheumatic Drugs
Alopecia-areata Universalis
Factor Antagonist Therapy
2012 Brazilian Society
Ankylosing-spondylitis
Country: NEW YORK
Editor: ELSEVIER SCIENCE INC
Rights: embargo
Identifier DOI: 10.1016/j.rbre.2014.06.006
Address: http://www.sciencedirect.com/science/article/pii/S2255502114001710
Date Issue: 2015
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
wos_000357440800012.pdf3.13 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.